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Abstract 
 
Atherosclerosis is a highly prevalent disease that can significantly increase the risk 
of major vascular events, such as myocardial or cerebral infarctions. The anoxemia 
theory states that a disparity between oxygen supply and demand contributes to 
atherosclerosis. Hypoxia inducible factor-1 (HIF-1) is a heterodimeric protein, part of 
the basic helix-loop-helix family and one of the main regulators of cellular responses 
in a low-oxygen environment. It plays a key role in the development of 
atherosclerosis through cell-specific responses, acting on endothelial cells, vascular 
smooth muscle cells (SMCs) and macrophages. Through the upregulation of VEGF, 
NO, ROS and PDGF, HIF-1 is able to cause endothelial cell dysfunction, 
proliferation, angiogenesis and inflammation. Activation of the NF-kB pathway in 
endothelial cells is an important contributor to inflammation and positively feedbacks 
to HIF-1. HIF-1 also plays a significant role in both the proliferation and migration of 
smooth muscle cells – two important features of atherosclerosis, while the formation 
of foam cells (lipid-laden macrophages) is also a critical step in atherosclerosis and 
mediated by HIF-1 through various mechanism such as dysfunctional efflux 
pathways in macrophages. Overall, HIF-1 exerts its effect on the pathogenesis of 
atherosclerosis via a variety of molecular and cellular events in the process. In this 
review article, we examine the effects HIF-1 on vascular cells and macrophages in 
the development of atherosclerosis, highlighting the environmental cues and 
signalling pathways that control HIF-1 expression/activation within the vasculature. 
We will highlight the potential of HIF-1 as a therapeutic target on the disease 
development.  
 
 
Keywords: HIF, endothelial cells, smooth muscle cells, macrophages, 
atherosclerosis 
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1. Introduction 
 
Atherosclerosis is a chronic inflammatory disorder that affects the arteries in the 
body and has a high association with comorbidities and mortality (Gao et al., 2012). 
It is the primary cause of coronary artery disease and stroke in the developing world 
(Jaipersad et al., 2014b) and most common cause of coronary artery disease and 
peripheral arterial disease worldwide (Sanchis-Gomar et al., 2016). The 
development of atherosclerosis is initiated by endothelial activation and involves lipid 
accumulation within the layers of the arterial wall, monocyte adherence, infiltration 
and the formation of a lipid core. Foam cell (lipid-laden macrophages) and smooth 
muscle cell proliferation are characteristic features of atherosclerosis. Monocytes 
migrate into the arterial intima where they proliferate and differentiate into 
macrophages. These macrophages proceed to take up oxidised LDL, forming foam 
cells. As a consequence of cell aggregation, initial lesions progress to advanced 
plaques. Production of reactive oxygen species (ROS) and ongoing inflammation 
leads to matrix degradation and a combination of cellular apoptosis and necrosis. 
This can cause eventual thinning of the fibrous cap on the plaque. Complications of 
atherosclerosis can include occlusion of the vascular lumen due to plaque growth or 
rupture of vessel wall and formation of a thrombus (Hansson, 2005).  
As the plaque develops, the arterial wall thickens, significantly reducing oxygen 
diffusion into the intima. There is increasing evidence to suggest hypoxia and oxygen 
disruption in the pathogenesis of atherosclerosis. The anoxemia theory of 
atherosclerosis states that a mismatch between oxygen supply and demand in the 
arterial wall leads to the development of lesions and plaques (Björnheden et al., 
1999).  This is thought to occur by a number of potential mechanisms, such as 
promoting lipid accumulation, increasing inflammation and angiogenesis (Hultén and 
Levin, 2009). However, despite the plethora of research, money and time invested in 
this field, there has been limited development of successful preventative and 
therapeutic treatments (Duguid, 1946; Grotel, 1945). In order for such treatments to 
be generated a greater understanding of the molecular events leading up to 
inflammation is required. One protein family of interest is hypoxia inducible factor 
(HIF).  
HIF is a known vascular transcription factor. It is heterodimeric and consists of two 
main subunits, α and β, but also has three forms, HIF-1, HIF-2 and HIF-3. It has 
been shown that in low oxygen concentrations HIF functions to a greater extent than 
in normal or high oxygen conditions. Hypoxia, decreases the usual hydroxylation of 
HIF, limiting its proteolytic degradation. HIF enhances the compliance of the both 
cells and tissue in hypoxic states; it affects mitochondrial oxygen consumption, 
regulates mitochondrial autophagy, increases serum erythropoietin (a protein coding 
for increased production of red blood cells that carry oxygen to the tissues), and 
more crucially, controls angiogenesis. A hot topic, attracting interest in the past 
decade, is the role of HIF in the progression of vascular diseases and how changes 
in its expression levels affect the resolution of such conditions. In addition to the 
known link between HIF and oncogenesis, HIF is also associated to angiogenesis 
occurring in vascular diseases, such as angiogenesis after thrombosis and stenosis, 
or the weakened vessel formation in atherosclerosis, which increases the risk of 
plaque rupture or total arterial occlusion. Although it is known that HIF plays a role in 
the progression of atherosclerosis, it is important to note that in some cases HIF may 
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play a beneficial role.  As demonstrated by revascularization and collateral 
circulation in ischaemic brains; HIF appears to be primarily induced in the penumbra 
– the salvageable tissue post ischaemia (Shi, 2009). Similar evidence of 
revascularization has also been found in non-ischemic tissue, such as corneal 
revascularization, which may increase the viability of the cornea in degenerative 
conditions or abrasions (Kelly et al., 2003). This review aims to evaluate the role of 
HIF in atherosclerosis and to highlight its potential as a therapeutic target for 
treatment of atherosclerosis. 
2. HIF family 
HIFs are critical mediators of the cellular response to oxygen. They belong to the 
Per-ARNT-SIM subfamily of the basic helix-loop-helix (bHLH PAS) protein family that 
can regulate cells in low oxygen environments. To date, 3 transcription factors have 
been discovered (HIF-1, 2, 3; Figure 1).   As HIF is a transcription factor, it 
determines angiogenesis and thus oxygen supply to tissues under hypoxic 
conditions, through the regulation of transcription of genes including Vascular 
Endothelial Growth Factor (VEGF) and Erythropoietin (EPO). VEGF is the major 
protein involved in promoting vessel formation throughout the organism life, whereas 
EPO controls erythropoiesis, the production of red blood cells. (Benizri et al., 2008; 
Formenti et al., 2010; Smith et al., 2008; Wilkins et al., 2016) 
The key regulator of hypoxia, HIF-1 is a ubiquitous transcription factor able to control 
the responses of nucleated cells in hypoxia. It is a heterodimer protein made up of 
HIF-1ß (its activity is unaffected by hypoxia) and HIF-1α - the active subunit, that has 
a half-life of 5 minutes and is highly regulated by oxygen (Salceda and Caro, 1997). 
HIF-1α is expressed in all nucleated cells (Lim et al., 2013) and enables a rapid 
response to hypoxia. A significant amount of energy is devoted to the continuous 
turnover of HIF-1α in normoxic conditions. HIF-1α allows cells to adapt to low oxygen 
environments by activating genes that alter energy metabolism (Semenza et al., 
1994), cell proliferation (Carmeliet et al., 1998b), angiogenesis and vascular 
remodelling (Rose et al., 2002). 
In non-hypoxic conditions, two specific proline residues on HIF-1α protein are 
hydroxylated in oxygen-dependent degradation domains by prolyl hydroxylase 
domain proteins (PHD). In addition to that, acetylation of a lysine residue allows for 
the binding of von Hippel-Lindau, which interacts with the elongin C protein. This 
facilitates the recruitment of an ubiquitin ligase complex, marking HIF-1α for 
proteasomal degradation. FIH-1 (Factor inhibiting HIF-1) is also able to inhibit HIF-1 
through the hydroxylation of asparagine residue 803. This blocks the transactivation 
activity, thus enabling the negative regulation of HIF-1. During hypoxia, the oxygen 
dependent activity of prolyl hydroxylase domain enzymes and FIH-1 are inactivated. 
Oxygen is required as a substrate for the enzymes to hydroxylate HIF-1 proteins, but 
as it is unavailable, it causes HIF-1α to accumulate and translocate to the nucleus 
(Wang et al., 1995). Here, it dimerises with the HIF-1ß subunit through a common 
helix-loop-helix bonding (Jiang et al., 1996), to form an active transcription factor and 
proceeds to form a complex with the hypoxia-responsive element (HRE) of target 
genes.  
HIF-2 is similarly made up of 2 subunits and structurally, is approximately 48% 
homologous to HIF-1. It therefore shares some properties with HIF-1α, such as 
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binding with HIF-1ß. HIF-2α plays an important role in development of the embryonic 
heart and provides essential protection against heart failure via catecholamine 
homeostasis in utero (Sun et al., 2015). Although HIF-1 is ubiquitous, HIF-2 appears 
to be cell type specific, including, but not limited to endothelial cells, cardiomyocytes, 
glial cells and hepatocytes (Wiesener et al., 2003). The involvement of HIF-2 in 
cancers through cell proliferation, angiogenesis, metastasis and resistance to 
chemotherapy, has been well established (Zhao et al., 2015).  
The role of HIF-3 is less understood. The gene is able to give rise to several variants 
of HIF-3α through the use of different promotor regions, different transcription 
initiation sites and varied splicing. Thus, these variants are expressed in different 
tissues at different development stages, with varied responses to hypoxia. There is 
strong evidence to suggest that some variants have contrasting functions (Rankin 
and Giaccia, 2008). HIF-3 plays an important role in the regulation of HIF-1 and HIF-
2. While some HIF-3 variants are able to act as dominant-negative regulators, other 
variants can inhibit HIF-1/2 (by competing for the binding of HIF-1ß) (Duan, 2016). 
As HIF-1α has been the focus of most studies, any reference to HIF will be regarding 
the HIF-1α subunit, unless otherwise stated. 
HIF activates gene transcription mainly by binding to a cis-acting regulatory element 
named “hypoxia response element (HRE)” as defined by the core DNA sequence 5’-
A/GCGTG-3’. Genome-wide chromatin immunoprecipitation (ChIP) assays have 
identified that HIF directly regulates the expression of more than 1,000 genes in 
human. Some examples of adaptive responses initiated under hypoxia include matrix 
metabolism (MMP-1, MMP-2, MMP-3), angiogenesis (VEGF, ENG, LEP), 
erythropoiesis (EPO) and cell proliferation (Cyclin G2, IGF2). Other than hypoxia, 
PHD enzymes can also be inhibited through other mechanisms, such as reactive 
oxygen species (Fe2+ is oxidized to Fe3+ – the depletion of the essential Fe2+ cofactor 
inactivates the enzymes) (Niecknig et al., 2012). 
Recent studies show that less than 2% of human DNA codes for protein and 98% is 
composed of various classes of non-coding RNAs, such as microRNA (miRNA), 
tRNA, snRNA and long non-coding RNAs (lncRNAs). Some of these have the 
potential to control gene expression via transcription, post-transcription and 
epigenetic regulation, and can often become dysfunctional in disease processes. 
MiRNAs stabilise and translate mRNA; long-non-coding RNAs have a more varied 
function, such as chromatin modification and have been reported to play a key role in 
HIF-1 regulation (Choudhry et al., 2016). The action of HIF-1 can be modulated in 
hypoxic condition. This may occr through both the upregulation and downregulation 
of specific non-coding RNA molecules. miR-210 has been studied in cells affected by 
tumours and cardiac disease. It plays a critical role in cell differentiation, proliferation 
and angiogenesis in hypoxic environments. When studied on murine models, it was 
able to improve angiogenesis and cardiac function in the treatment of heart disease 
(Hu et al., 2010). Although they play a major regulatory role, it is important to note 
that a direction relationship between non-coding RNA molecules and HIF 
transactivation was not found. Furthermore, much of the research between non-
coding RNA and HIF exists in the context of cancer and oncogenesis, as opposed to 
atherosclerosis (Shih et al., 2017).  
The role of these HIF-1-dependent homeostatic mechanisms in the pathophysiology 
of atherosclerosis is described in greater detail below. 
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3. HIF and endothelial cells 
As endothelial cells are the first layer in contact with blood, it is important they are 
able to regulate vascular homeostasis. This is maintained through various 
mechanisms such as anti-thrombotic functions, recruitment of inflammatory 
mediators and the endothelial cell effect on vascular tone. These mechanisms are 
altered when the vasculature experiences hypoxia (Ten and Pinsky, 2002). Through 
the activation of HIF-1α, the cell is able to adapt to lower metabolic needs in a low 
oxygen environment. Both directly and indirectly, more than 2% of all human genes 
are regulated by HIF-1 in endothelial vascular cells (Manalo et al., 2005).   
 
HIF-1α causes major alteration within endothelial cells, through 3 main ways: 
vascular endothelial growth factor (VEGF), nitric oxide (NO) and reactive oxygen 
species (ROS). An upregulation of VEGF, free radicals and nitric oxide production, 
along with platelet-derived growth factor (PDGF) promote the development of 
atherosclerosis. This is worsened by endothelial cell dysfunction, endothelial cell 
proliferation, angiogenesis and inflammation (Gao et al., 2012). Overproduction of 
free radicals and ROS lead to a large disruption of endothelial cell function 
(Madamanchi et al., 2005). In hypoxia, two major responses have been observed in 
endothelial cells, which depend on the severity and duration of oxygen loss. Acute 
hypoxia leads to activation of endothelial cells, causing them to release inflammatory 
mediators and growth factors that promote the adherence of phagocytes (such as 
neutrophils and macrophages) to the vascular wall. Over a longer period of time, 
hypoxia causes transcriptional induction of genes such as Glut-1 (involved in 
transendothelial glucose transport), VEGF and iNOS (inducible nitric oxide 
synthase), enabling cells to survive in low oxygen environments (Harris et al., 2014) 
(Figure 2).  
 
HIF-1 upregulates the production of VEGF by binding to the hypoxia response 
element (HRE) in the VEGF promoter region. VEGFR-1 and VEGFR-2 are the two 
main receptors expressed on endothelial cells, both mediated by HIF-1 (Kaur et al., 
2005). The upregulation of VEGFR-1 is directly induced by HIF binding to the 
enhancer element within the VEGFR-1 promoter region, whereas the expression of 
VEGFR-2 during hypoxia is via post-transcriptional regulation. VEGF acts as a 
chemotactic and mitogenic factor on endothelial cells via both VEGFR-1 and 
VEGFR-2 causing cell proliferation, migration, enhancing cell permeability and 
angiogenesis (Tang et al., 2004).   
 
The production of NO is regulated by HIF-1 through 2 major mechanisms: increasing 
iNOS and subunit 4-2 of cytochrome c oxidase (COX4-2). In order to increase 
perfusion, HIF-1 activates iNOS which increases NO production and leads to 
vascular vasodilation, increasing blood and oxygen  supply to cells (Hendrickson 
MD, 2015). Interestingly, some studies have reported that iNOS is able to positively 
regulate VEGF expression, however this was seen specifically in tumorigenesis (Van 
der Wall, 2006; Wang, 2001).  
 
Several studies have been done to assess the individual phenotypic processes 
involved in angiogenesis such as cell migration or cell proliferation of endothelial 
cells. There have been conflicting results with some studies showing hypoxia 
activating endothelial cell proliferation (through stimulation by adenosine) (Meininger 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 7 
et al., 1988) and others showing a reduction in proliferation (Shreeniwas et al., 1991; 
Tucci M, 1997). However, the exact reason for these differences is unclear, due to 
the nature of in vitro testing and isolated system use, it could be caused by varying 
severity of hypoxia, type of endothelial cell used (human vs bovine) or other factors, 
such as integrated counter-regulatory controls.  
  
One study concluded that although endothelial cells were able to grow and survive in 
hypoxia, they had altered function. Their growth was slower in hypoxia, and despite 
a confluent monolayer being achieved in vitro, the cells were larger in size. That in 
addition to an altered actin-based cytoskeleton seen post-hypoxia, meant that 
adjacent cells had small gaps, leading to increased permeability of the vasculature 
(Meininger et al., 1988). 
 
It has been well recorded that HIF-1 activation correlates with atherosclerotic 
disease progression and inflammation (Sluimer et al., 2008; Vink et al., 2007). In 
atherosclerotic endothelial cells, CXCL1 and TNFα were found to be the two most 
significant pro-inflammatory cytokines released. Mildly oxidized-LDL (and its 
derivative LPA) induced pro-inflammatory status in endothelial cells through the 
upregulation of HIF-1α. An increased expression of miR-19a, a non-coding RNA 
molecule that regulates gene expression, led to the activation of the NF-kB 
inflammatory pathway and pro-inflammatory cytokine release. Endothelial NF-kB 
activation also upregulates HIF-1 expression via creating a positive feedback loop. 
Alternatively, endothelial cells deficient in HIF-1 had a downregulation of miR-19a in 
atherosclerotic arteries (Akhtar et al., 2015). Thus, they were able to conclude that 
hyperlipidemia caused an increase in HIF-1 production and endothelial cell 
activation. HIF-1 accumulates in cells primarily due to protein stabilisation in hypoxia, 
however glycolysis (an anaerobic process) is the main form of energy in endothelial 
cells and oxygen supply is not limited to endothelial cells via the blood stream, at 
least in the primary stages of the disease. Thus, non-hypoxic stimuli such as 
angiotensin II, TNFα or MoxLDL may be more important for the activation of HIF in 
endothelial cells, at least in the initial stages of atherosclerosis.  
 
4. HIF and smooth muscle cells 
 
The proliferation and migration of smooth muscle cells from the media to the intima 
is one of the key features of the atherosclerotic process. One of the first signs of 
atherosclerosis is a pathological thickening of the intima (de Groot et al., 2008). It 
has been documented that hypoxia, more specifically HIF-1α, is a stimulus of 
vascular remodelling – ultimately leading to a narrowing of the arterial lumen 
(Diebold et al., 2008; Schultz et al., 2009). Migration Inhibitory Factor (MIF) has been 
described as an important mediator of this process. Under hypoxic conditions, HIF-
1α is upregulated, causing an overexpression of the MIF gene (alternatively, a 
knockout of the HIF-1α gene in human umbilical artery smooth muscle cells - 
HUASMCs - inhibited MIF production) (Fu et al., 2010). MIF is an important 
upstream product of the inflammatory cascade and has been associated with foam 
cell transformation along with vascular remodelling. Hypoxia led to the activation of 
several mediators such as ROS and extracellular signal-regulated kinase (ERK). 
Blocking both (with an antioxidant and PD98059 respectively), caused a decrease in 
hypoxia induced HIF-1 expression, indicating their importance in the process. 
HUASMCs were cultured in hypoxia (3% oxygen) and proliferated 113.6% more than 
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cells cultured in normoxia. Furthermore, there was only partial proliferation in MIF-
siRNA blocking cells and no proliferation seen in HIF-1 knockout cells, suggesting 
that MIF is involved in HUASMC proliferation. The effect of MIF in cell migration was 
assessed in a similar manner, resulting in identical findings. MIF-siRNA partly 
prevented migration in both hypoxia and normal conditions. Over expression of HIF 
caused increased HUASMC proliferation, even in normoxia and knockdown of HIF 
expression prevented any hypoxia induced migration (Fu et al., 2010) 
 
Thrombospondin-1 (THBS1) expression has been associated with migration of 
human vascular smooth muscle cells (VSMC) (Ichii et al., 2001; Patel et al., 1997). 
However, the factors that regulate the migration of VSMCs in hypoxia are still being 
explored. It has been found that THBS1 is upregulated in hypoxic conditions via the 
HIF-1α pathway (Phelan et al., 1998). Hypoxia-induced migration of VSMCs was 
inhibited by a neutralising antibody against THBS1 and by a RDG peptide binding to 
integrin ß3. Supporting previous evidence of the relationship between integrin ß3 
and THBS1 in migration (Sajid et al., 2000). Neutralising antibodies to THBS1 did not 
affect hypoxia-induced DNA synthesis, suggesting that THBS1 is unlikely to be 
involved in VSMC proliferation, but rather migration. It is more likely that proliferation 
is due to a different HIF-dependent pathway such as PDGF or fibroblast growth 
factor (FGF) (Schultz et al., 2006). HIF-1 knockdown led to a decrease in hypoxia 
induced THBS1 and subsequent reduction in cell migration. Simultaneously, an 
overexpression of HIF-1 led to increased migration compared to control cells 
(Osada-Oka et al., 2008).   
 
It is well known that PDGF is involved in proliferation and migration of VSMCs, 
however its exact relationship in hypoxia is less well known. PDGF-dependent 
proliferation and migration of smooth muscle cells is increased in hypoxia, with PI3K 
and PLCy important mediators of the pathway. Chronic hypoxia leads to an 
accumulation of HIF-1 in VSMCs, causing a decrease in expression of PDGFR-
antagonising protein tyrosine phosphatases (PTPs). These PTPs are important 
negative regulators and in their absence, ligand-induced PDGFR phosphorylation is 
enhanced, along with cellular proliferation and migration. Pharmacological inhibition 
of PI3K and PLCy prevented PDGF-dependent migration and proliferation in both 
hypoxic and normal oxygen environments, suggesting that the hypoxia sensitive 
signalling molecule is proximal in the signalling pathway, although the exact 
mechanism is unclear (Freyhaus et al., 2011). One study did hypothesise that cell 
proliferation was linked to the stimulation of cyclin A gene transcription (Schultz et 
al., 2006).  It is also important to mention that hypoxia alone (without ligand binding) 
did not lead to PDGF-dependent proliferation or migration, eluding to an indirect 
hypoxia induced receptor activation and phosphorylation (Freyhaus et al., 2011). 
 
Similar mitogenic cellular responses (increased migration and proliferation of 
VSMCs) were seen when using fibroblast growth factor-2 (FGF-2) and epidermal 
growth factor (EGF) - also 2 tyrosine kinase-receptor activating growth factors. 
Interestingly, hypoxia did not induce mitogenic effects in the presence of mitogens 
that signal via serine/threonine kinase receptors (such as TGF-ß) or via G protein 
coupled receptors (thrombin and angiotensin II). It is not clear whether the reason for 
this is the selective influence of hypoxia on mitogens or whether it is due to the level 
of hypoxia or inadequate expression of receptors/downstream signalling molecules.  
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5. HIF and macrophages 
 
An accumulation of macrophages and their uptake of oxidised LDLs is an important 
feature in atherosclerosis. It is widely known that macrophages are major 
contributors to atherosclerotic progression (Nakashima et al., 2007). HIF-1α is able 
to activate pro-angiogenic genes in macrophages, such as TNFα and VEGF. It also 
appears to play a critical role in the maturation of macrophages (Fang et al., 2009). 
Monocytes produce PDGF that causes mitotic division of both vascular smooth 
muscle and endothelial cells, contributing to the vascular remodelling process in 
disease progression. Once activated, the monocytes and macrophages that have 
infiltrated the plaque, as a result of increased permeability and local inflammation, 
take up oxidized lipids and become foam cells (Figure 3). Foam cells have a similar 
contribution of vascular remodelling by stimulating migration in smooth muscle cells 
(Kruth, 2001). Although macrophages are derived from the monocyte lineage, once 
monocytes have infiltrated the tissue layers of the blood vessel, a considerable 
number of them will differentiate into dendritic cells. This leads to a subsequent 
activation of T lymphocytes via specific antigens contributing to local inflammation 
(Elsheikh et al., 2005).  
 
The ability of cells to remove excess cholesterol is important for survival and most of 
them do this via efflux pathways. For the efflux of cholesterol, both a plasma 
membrane transporter and cholesterol acceptor are required. Under hypoxic 
conditions cholesterol and triglyceride levels were significantly higher in human 
macrophages. Interestingly, the cholesterol content was different as well. 
Macrophages cultured in hypoxia showed a higher percentage of unesterified 
cholesterol, which can be toxic to human macrophages (Liu et al., 2007). Normally 
macrophages are able to esterify free cholesterol into cholesteryl esters for storage 
as lipid droplets, however, as expected, cholesteryl esters were significantly lower in 
hypoxic macrophages. Under hypoxic conditions, the overexpression of HIF-1 
caused a decrease in cholesterol efflux in macrophages, leading to the formation of 
foam cells. The ability of ABCA1, the major cholesterol efflux transporter in 
macrophages, had a substantially reduced function (84% decrease) compared to 
macrophages in normoxia (Parathath et al., 2013). Alternatively, HIF-1 knockdown 
cells in hypoxic conditions showed decreased HMG CoA reductase mRNA leveels, 
higher efflux of cholesterol, reduced triglyceride levels and lower total cholesterol 
content.  
 
A lack of HIF-1α in macrophages led to a reduced inflammatory phenotype 
compared to control cells. mRNA expression of osteopontin and MCP-1 (monocyte 
chemoattractant protein – 1) was decreased under normoxic conditions in HIF-1 
knockout macrophages. The expression of iNOS was also reduced in HIF-1 
knockdown cells compared to the wild type. In addition, HIF-1 was able to regulate 
the polarisation of macrophages into the M1 or M2 phenotype. Upon differentiation 
into the pro-inflammatory M1 phenotype, through interferon γ and 
lipopolysaccharide, HIF-1α deficient cells showed a lower expression of M1-typical 
genes compared to control cells. However, in M2 polarisation by interleukin-4, HIF-
1α knockdown macrophages showed no significant difference. Thus the elimination 
of HIF-1α from macrophages blunts the pro-inflammatory phenotype of M1 
macrophages (Aarup et al., 2016b).  
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The retention of apoB-100-containing lipoproteins within the arterial wall seems to be 
a critical step in the development of plaques. This process is mediated by the 
negatively charged glycosaminoglycan (GAG) chains on proteoglycans in the intima 
and the positively charged parts of apoB-100. HIF-1α has been associated with the 
production of proteoglycans by macrophages, such as versican. Furthermore, 
knockdown of HIF-1α inhibited hypoxia induced production of versican (Heikal et al., 
2016).  It was also found that human monocyte derived macrophages exposed to a 
hypoxic environment for longer, secreted GAGs that were more sulphated and 
displayed a higher affinity for LDL. Indicating that changes in the biosynthesis of 
macrophages induced by hypoxia may play an important role in the development of 
atherosclerosis (Asplund et al., 2011).  
 
The contribution of macrophages and macrophage-derived HIF-1 to arterial 
remodelling has been recorded both in vitro and in vivo models. There is a significant 
contribution from HIF-1 to local inflammation due to the production of pro-
inflammatory cytokines and chemokines, such as IL-6 and TNF-α. HMGB-1 is a 
nuclear protein present after arterial injury that contributes to the inflammatory 
cascade (increased HMGB-1 expression has been seen in necrotic tissues and 
atherosclerotic plaques). To determine the role of HIF-1 deficient macrophages in 
secreting pro-inflammatory cytokines, HMGB-1 was used as a stimulant. Under both 
hypoxic and normal conditions, HMGB-1 led to an increased level of HIF-1 and 
subsequent elevation of HIF-1 responsive genes (such as Glut-1 and VEGF). 
However, in HIF-1-deficient macrophages, there was a significantly blunted response 
to HMGB-1 stimulation, indicating the importance of the HMGB-1/HIF pathway in 
vascular remodelling.  
 
There was no significant difference found in macrophage proliferation in hypoxia 
compared to normal conditions. HMGB-1 was similarly used for stimulation in both 
normal macrophages and HIF-1 deficient macrophages, with no statistical difference 
being noted. Suggesting HIF-1 may not play a major role in proliferation of 
macrophages. The migration of macrophages however, was influenced by HIF-1. 
After MCP-1 stimulation, HIF-1 deficient macrophages showed reduced migration, 
both in normoxia and hypoxia (Nakayama et al., 2013). 
 
6. HIF and atherogenesis  
 
The final stage of plaque development inflammatory cytokines and chemoattractants 
produced within the plaque, including IL-1β produced by the enlarging foam cells 
and PDGF, induce the infiltration of proliferating SMCs into the plaque. Collagen 
production is also stimulated. This limits the vessel compliance and increases the 
stiffness of the arterial wall. Additional cells are subsequently recruited, including T 
cells and dendritic cells. Vessel wall rigidity predisposes the wall segment to rupture 
whereby platelets will then accumulate, in response to exposed collagen and tissue 
factor, and form a fragile fibrous cap. This further reduces elasticity and risks the 
development of thrombosis, which could fully occlude the vessel or embolise to a 
distal area. Parallel to these processes, a major risk factor for the development of the 
plaque and the progression of complications is the formation of new weak vessels. 
HIF, which is expressed within the core of the atherosclerotic plaque, induces the 
expression of VEGF and is associated with angiogenesis. This angiogenesis 
involves the invasion and formation of new vessels sprouting from the vasa vasorum; 
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the arterial network supplying the adventitia – the most external of the three layers of 
the vessel wall. This not only increases the haemodynamic instability and fragility of 
the plaque, but also allows further infiltration of inflammatory cells, thus additionally 
increasing the inflammation in the atherosclerotic lesion (Libby et al., 2011; Sluimer 
and Daemen, 2009). There is a clear correlation between the growth and potential 
rupture of the atherosclerotic plaque and the expression of VEGF and HIF. Research 
indicates that adventitial microvessels are more numerous in vulnerable and older 
plaques, implying that the HIF and the angiogenic pathway is key in atherosclerosis 
and the progression to its life-threatening complications (Kamat et al., 1987; 
Lappalainen et al., 2004; Mofidi et al., 2001; Moreno et al., 2004; Sluimer and 
Daemen, 2009). 
 
Nuclear HIF-1α has been found to be present in atherosclerotic plaques, suggesting 
that HIF-1α was in its active form in these areas, and translocated to the nucleus in 
order to induce transcription of genes. This was observed in human carotid and 
femoral endarterectomy specimens, of which about half showed a positive staining 
for macrophages. (Vink et al., 2007) Furthermore, pimidazole, a stain indicating 
hypoxia, showed increased hypoxic regions in the atheroscleorotic core, thus 
implying the association of hypoxia with the development of atherosclerosis. In 
addition, pimidazole was also co-localised with CD163, a specific marker of 
macrophage receptor. In measuring the expression of HIF-1α of these cells, it was 
found to be augmented compared to normal vessel wall segments, inferring the role 
of macrophage HIF in the progression of atherosclerosis (Aarup et al., 2016a). Co-
localisation of macrophages and HIF1α within the plaque is supported by additional 
studies, (Luque et al., 2008) including data produced by the use of nuclear staining 
and CD68+, another known macrophage marker (Higashida et al., 2008; Vink et al., 
2007). Findings suggested that the plaque haemorrhage is a common phenomenon 
in plaques with increased numbers of macrophages, underlining their importance in 
atherosclerosis. Another important finding is that the expression of PR39, a 
macrophage derived protein known to inhibit the degradation of HIF-1α, was greatly 
increased under hypoxia, in both human and animal cells. Cells secreting this protein 
are also found in the coronary vasculature. PR39 may be important in explaining the 
connection between inflammatory cells, HIF-1α and atherosclerosis, however, further 
work is required (Li et al., 2000). 
 
HIF1α is known to control the recruitment of progenitor cells that attempt to repair 
the ischaemic tissue by inducing the expression of stromal cell-derived factor (SDF-
1α) (Marsch et al., 2013). However, it is thought that the increase in progenitor cells 
in the necrotic plaque area may additionally lead to a rise in inflammation and in the 
vulnerability of the lesion. Research studying the exposure of vascular and 
perivascular areas to hypoxia, indicated a 7 and 12-fold increase in the expression of 
SDF-1 after 6 and 9 hours of 1% oxygen exposure respectively. Furthermore, HIF-1α 
and SDF-1 were co-localised in approximately 75% of endothelium of arteriole and 
capillary lining, a finding which was absent in the lack of HIF oxygen dependent 
degradation domain, induced by genetic modification, signifying the hypoxic element 
of the process. It is hence proposed that a pharmacological blocker of HIF targeting 
endothelial cells would decrease inflammation and result in a less fragile plaque, 
decreasing the risk of complications (Ceradini et al., 2004). 
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Similarly, it has been suggested that SMCs are also involved in the function of HIF in 
the atherosclerotic progression. The genetic knockout of HIF-1α in SMCs in 
atherosclerosis predisposed apolipoprotein E knockout mice causing a decrease in 
the plaque size, but also reduced the inflammation of the site. Therefore, it can be 
assumed that HIF expression in SMCs guides the worsening progression of 
atherosclerosis (Liu et al., 2016). However, there is opposing evidence advocating 
that SMC derived HIF has a protective role in aneurysms, another disease process 
involving atherosclerosis. Here it was found that the deficiency of HIF-1α in SMCs 
augmented aortic aneurysms, by disturbing the formation of elastic fibres, but not by 
effecting the pre-existing arterial fibres. The difference may be explained by the fact 
that aneurysms are mostly caused by the change in metalloproteinases and 
compliance of the weakening arterial wall, whereas stenosis due to atherosclerosis 
leads to fragile, harden walls. Further work is necessary to clearly establish the 
protective role of HIF (Imanishi et al., 2016). 
 
 
7. HIF and angiogenesis  
 
As mentioned above, angiogenesis occurs in late stage atherosclerosis, i.e. vasa 
vasorum formation, in which HIF-1 plays a major role. This factor is known to 
mediate apoptosis and increase vessel formation through controlling the expression 
of VEGF, a major angiogenic factor. The link between angiogenesis and HIF was 
made clear though experimentation with transgenic mice. These mice expressed 
constitutively active HIF-1α in the epidermis, which led to approximately a 65% 
increase in the dermal vascularity, as measured by quantification of 
microvasculature vessel length and density. In addition to this, PCR measurement of 
VEGF expression in these mice showed a 13-fold increase in total VEGF expression 
when compared to wild-type controls (Elson et al., 2001). In situations where the loss 
of HIF-1 was induced, VEGF expression was reduced, again suggesting a major link 
between the two factors (Role of HIF-1 in hypoxia mediated apoptosis, cell 
proliferation and tumour angiogenesis) (Carmeliet et al., 1998a). 
 
The importance of VEGF is clear in the embryonic stages of vessel development. 
Research done, involving the study of VEGF mutant embryos found that 
heterozygous mutants presented with a great number of vascular anomalies, when 
compared to wild type embryos, while homozygous VEGF mutants were difficult to 
study as many died. The defects seen in the heterozygous VEGF mutants resemble 
the vessel abnormalities in HIF-1 mutant embryos. The link between the two factors 
was confirmed in this HIF-1 mutant model, as co-transfection of the embryonic cells 
with HIF-1α and HIF-1β activated VEGF expression in a 5-fold increased manner 
under normoxic conditions and in approximately 77-fold increase under hypoxic 
conditions, when compared to cells with no cotransfection (Carmeliet et al., 1996). 
Additionally, evidence suggests that neovascular formation requires the inflammatory 
process of endothelial activation, which involves VEGF interaction with its receptors. 
This is thought to alter the interactions between endothelial cells and SMCs 
(Thurston et al., 1999). 
 
The atherosclerotic core consists of an inflammatory, highly cellular environment with 
elevated metabolic stresses. The resulting imbalance of oxygen supply versus 
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oxygen demand causes the impression of a hypoxic setting, which induces the 
expression of HIF. This is followed by the production of VEGF, which as discussed 
above increases the vascularity of the area. The inflammatory evolution of the region 
is progressed, more cells reach the necrotic core, intensify the metabolic demand 
and severity of the hypoxic state and thus further increase the HIF and VEGF 
expression (Libby et al., 2011). 
 
Long-term adaptation to hypoxia is primarily achieved through the process of 
angiogenesis. It is a major consequence of hypoxia as a result of various HIF 
dependent genes such as VEGF, endothelin-1 and matrix-metalloproteinase-2 
(Semenza, 2003). HIF-1α is able to directly activate VEGF by binding to HRE, 
allowing for transcription of the protein. Many studies have been able to establish the 
role between HIF-1 and VEGF expression. VEGF is a pro-angiogenic growth factor, 
mainly responsible for the formation of new capillaries. Developmentally, it is 
required in embryonic angiogenesis, but pathologically it is seen in many diseases 
such as tumours, atherosclerosis and retinal eye disease. It mainly acts through the 
binding of tyrosine-kinase receptors (Forsythe et al., 1996). As previously mentioned, 
the process of angiogenesis and neovascularisation is thought to be a key 
contributor to the progression of a stable asymptomatic plaque to an unstable and 
rupture prone one. A 2-4 fold increase was observed in the number of vasa vasorum 
in ruptured or vulnerable plaques compared to stable ones (Virmani et al., 2005). A 
clear association between the angiogenesis and the presence of new vessels in a 
plaque has been linked to its rupture (Kumamoto et al., 1995).   
 
In hypoxia, the accumulation of HIF activates gene transcription for VEGF and 
VEGFR. VEGF produces a pro-angiogenic environment through mobilising 
endothelial cells (Inoue et al., 1998). Aggressive plaque development and 
accelerated angiogenesis was seen in rabbit models when administered VEGF 
(Celletti et al., 2001). VEGF is expressed by many cells including macrophages, T 
lymphocytes and endothelial cells and causes production of chemoattractant 
proteins such as MCP-1 that causes cell migration and increases the permeability of 
the endothelial layer. The basement membrane is partly degraded by digestive 
enzymes such as matrix-metalloproteinases, allowing a fibrin matrix of plasma 
proteins to form with a lumen, where endothelial cells migrate. Physiological 
angiogenesis has sprouts that are supported with basement membrane formation 
and smooth muscle (and pericyte) cell recruitment (Dvorak et al., 1995). Pathological 
angiogenesis, as seen in atherosclerosis and tumours, is characterised by extensive, 
thin-walled vasculature that is prone to collapse. The endothelium is unable to 
control leakage adequately in pathological angiogenesis due to disruption of the 
intercellular junctions, a major contributor to the cause of intraplaque haemorrhage in 
atherosclerosis. It is thought the genes responsible for angiogenesis are similarly 
responsible for atherosclerotic development through plaque destabilisation, 
inflammation and plaque haemorrhage (Michel et al., 2011).  
 
VEGF expressed by macrophages activates MCP-1 in endothelial cells and 
increases the permeability of the endothelial layer, leading to chronic low level 
inflammation and monocyte infiltration. The monocytes and macrophages in the 
lesions express proteases such as urokinase plasminogen activator. This enables 
them to interact with substances in the extracellular matrix such as proteoglycans 
and collagen. Urokinase plasminogen activator initiates plasmin in the breakdown of 
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the extracellular matrix; an important step in angiogenesis and vascular remodelling 
(Menashi et al., 1993). The expression of E26 transformation-specific sequence 1 
(Ets-1) is induced by HIF1 directly and indirectly via VEGF (Oikawa et al., 2001). Ets-
1 contributes to angiogenesis through the proliferation of endothelial cells and 
converting them to the angiogenic phenotype (Oda N, 1999). Ets-1 and VEGF are 
able to enhance the expression of the other and create a positive feedback loop to 
facilitate angiogenesis.  
 
Angiogenesis is a complex process and although the majority of the discussion has 
focussed on VEGF, several other genes regulated by HIF-1 are also involved, such 
as Angiopoietin 1 (ANGPT1), ANGPT2, placental growth factor (PLGF) and Platelet-
derived growth factor b (PDGFB). Although HIF-1 directly regulates the transcription 
of VEGF, it is unclear whether the regulation of ANGPT1, ANGPT2, PLGF and 
PDGFB is direct or indirect (Hirota and Semenza, 2006). HIF-1 mediated VEGF 
response does not appear to be cell type specific, that is to say, whether endothelial 
cells, VSCMs or macrophages are concerned, hypoxia leads to a similar response. 
However, depending on the cell type, expression of ANGPT1 and ANGPT2 was 
either activated or suppressed in response to hypoxia. In arterial endothelial cells, 
hypoxia-induced ANGPT2 expression was suppressed in VSMCs and unchanged in 
cardiac myocytes and fibroblasts. The underlying molecular mechanism remains to 
be established (Kelly et al., 2003). ANGPT2 seems to be implicated in the 
angiogenic process and is upregulated in ischemic tissue (Jaipersad et al., 2014a). 
The binding of ANGPT2 is via a receptor called TIE-2, expressed largely in 
endothelial cells. TIE-2 is involved in the stabilisation of mature blood vessels and 
promotes the relationship between endothelial cells and periendothelial cells 
(Thurston, 2003).  
 
Interestingly, the adrenergic system has been shown to be involved in angiogenesis 
and the regulation of pro-angiogenic factors. Although the exact role of 
noradrenaline-mediated VEGF upregulation in atherosclerosis is unclear, it was 
found that a post-transcriptional mechanism was involved in noradrenaline mediated 
HIF-1 production and VEGF modulation (Park et al., 2011).  
 
PHDs serve as an oxygen sensor to regulate HIF hydroxylation and subsequent 
adaptive cellular response under different oxygen tension. The studies from 
Mazzon’s group (Hamm et al., 2013; Takeda et al., 2011) showed that hind limb 
ischemia induced ANGPT1 dependent PHD2 repression and ANG receptor TIE-2 
induction to form a feed-forward loop in macrophages. PHD2 haplodeficiency 
skewed macrophage polarization towards a pro-arteriogenic phenotype, hence, 
prevented ischemia by inducing arteriogenesis.  
 
8. Summary and perspectives  
 
Atherosclerosis is the principal process that results in many of the cardiovascular 
events, including coronary heart disease, critical limb ischaemia, and formation of 
emboli leading to strokes and myocardial infarctions. HIF is known to be a chief 
element in the induction of angiogenesis. The destabilized angiogenesis occurring in 
the ischaemic and necrotic atherosclerotic lesion is stimulated by HIF expression. 
This is one of the main potentiators of plaque rupture, which then leads to 
complications and the development of the mentioned diseases. Studies show that 
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the expression of HIF within the plaque is detrimental, specifically expression in 
SMCs, ECs and even more importantly macrophage and foam cells lead to a 
worsened outcome. However, there is little data concerning the targeting of HIF in 
order to pursue and seek the effects of its pharmacological inhibition.  
 
Predominantly through transcriptional activation, HIF-1α is able to regulate the 
response of endothelial cells, macrophages and smooth muscle cells to promote the 
development of atherosclerosis.  Cell proliferation, migration, angiogenesis, foam cell 
formation and a pro-inflammatory environment are the major consequences. 
However, to say that HIF-1α is an atherogenic factor would be inappropriate, as the 
response it induces is cell-type specific. Indeed, one study found that the 
overexpression of HIF-1α in lymphocytes, led to inhibition of plaque progression in 
murine (Ben-Shoshan et al., 2009). Given the role of HIF-1α as the main regulator of 
adaptive responses to hypoxia, it presents as a key therapeutic target. Much 
research has gone into the regulation of HIF-1α, through pharmacological 
intervention to slow or inhibit disease progression, however numerous problems 
have been faced. Firstly, the hypoxia-signalling pathway is imperative for several 
physiological processes and thus systemic targeting could cause undesirable effects. 
Furthermore, as HIF-1α plays a major role in angiogenesis, upregulation may 
actually be beneficial for patients with ischaemic diseases. Targeting HIF-1α too late 
in the atherosclerotic process could trigger the rupture of fragile plaques, leading to 
disastrous consequences (Figure 4).   
 
Furthermore, the research conducted tends to examine primarily one of the two 
subunits of HIF-1: HIF-1α, and there is little data available focusing on the role of 
HIF-1β or on HIF-2, another factor subtype. Hence, further research differentiating 
the factor roles may be useful in acquiring a clear picture. Additionally, as highlighted 
by the literature, there is a great difference between local and systemic effects of HIF 
action, and similarly there are differences in the effects of its inhibition. There is 
much debate regarding the available literature, as much data suggests that on a 
systemic level HIF improves the outcome of cardiovascular diseases as it stimulates 
the formation of collateral vascular networks. The local effect, the expression of HIF 
within the plaque itself and not wholly in the organism, is what this report has 
focused on and given that there is little accessible research specifically regarding the 
local consequences, the idea of HIF being a potential therapeutic target is supported 
but has yet to be proven.  
 
Although no clinical trials have been directly focused on the hypoxia signalling 
pathways, findings in animal models have shown promising results. Local inhibition 
of HIF-1 signalling in ApoE-/- mice significantly suppressed atherosclerotic plaque 
growth (Christoph et al., 2014). HIF-1 shows greatly versatility as a therapeutic target 
and some studies have raised the idea of altering the HIF-1 pathway to increase the 
bactericidal capacity of phagocytes, for infectious diseases (Zarember and Malech, 
2005). An advantage of targeting host molecules that encourage macrophage 
recruitment against pathogens, is the lack of selective pressure for resistance.  
Future studies will be most beneficial by focusing on the HIF-1α inhibition in specific 
cell types and investigating the outcome in both ischaemic and atherosclerotic 
patients.  
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In terms of therapeutic studies published, there is a niche to be covered with regards 
to the local targeting of HIF in atherosclerosis. Most models studied relative to HIF in 
cardiovascular conditions concentrated on the administration of the factor itself, or 
the induction of its expression and the subsequent development of collateral vessels 
in ischaemic situations. The concept of atherosclerosis and the local outcome of the 
factor action were not examined (Benizri et al., 2008; Vincent et al., 2000). Moreover, 
research examining the antiangiogenic treatment used in the case of thrombosis 
showed that the therapy led to limited thrombosis resolution. Despite the discrepancy 
that this finding proposes with regards to this review, the development and resolution 
of thrombosis differs greatly compared to atherosclerosis, in terms of cells, 
inflammatory mediators and initiation of the processes. In addition, this study 
focused on venous thrombosis, which is much different to any arterial event (Evans 
et al., 2014). Evidence regarding in vivo studies as well, implies that the role of HIF is 
of great significance in the inflammatory process of atherosclerosis but the use of its 
pharmacological blockade in atherosclerosis has yet to be recorded and published. 
As the factor has a very particular and local role in atherosclerosis, one of the issues 
faced is the difficulty in assuring that the mediator administered for its inhibition will 
reach the atherosclerotic site, without its metabolism or reach at other areas of 
hypoxia or inflammation. Perhaps an idea to be implemented could be to target the 
specific cells, which actively express HIF in atherosclerosis, urging its development. 
HIF derived from macrophages, SMCs and progenitor endothelial cells, involved in 
the process by using additionally cell markers, may consist of convenient and 
effective targets. In the hope that such an agent is created, it is important to block 
the inflammatory aspect of the process, which has a detrimental effect on 
atherosclerosis progression. This aspect calls for greater research.   
 
In summary, HIF plays a key role in the complex progression of atherosclerosis, and 
greater HIF expression and consequent intraplaque vascularization development is 
associated with increased plaque instability and worsened outcomes. The 
therapeutic role of HIF in atherosclerosis has been suggested, although there has 
been limited investigation into its potential. Further research in this field would 
provide a great potential for treatment of patients with severe atherosclerosis in 
clinic.  
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Figure legends 
 
Figure 1. The domain structure for HIF-1α, HIF-2α, HIF-3α and HIF-1ß. The bHLH 
and PAS regions are required for the heterodimerisation of the α and ß subunits. The 
oxygen dependent degradation domain (ODDD) region mediates the stability of the 
molecule through the hydroxylation of the two proline (P) residues and acetylation of 
lysine (K). Both HIF-2α and HIF- 3α are also regulated in a similar oxygen dependent 
manner through P and K residues. HIF-1α has 2 trans-activating domains (N-TAD 
and C-TAD), similar to HIF-2α, but HIF-3α and HIF-1ß only have one TAD. The N 
terminus is a bHLH that allows for DNA binding, and the C terminus recruits 
transcriptional regulatory proteins. The number at the end represents the number of 
amino acids in the subunit.  
 
Figure 2. The regulation of endothelial cells by HIF-1 – In hypoxic conditions, 
HIF-1α and HIF-1ß dimerise into the active form of HIF-1. Through the up regulation 
of nuclear factor kB (NF-kB), vascular endothelial growth factors (VEGF), their 
receptors (VEGFR), reactive oxygen species (ROS), free radicals (FR) and nitric 
oxide synthase (iNOS) leads to endothelial cell (EC) dysfunction, migration and 
proliferation contributing to the progression of atherosclerosis. 
 
Figure 3. The regulation of macrophages via HIF-1α – HIF-1 promotes 
inflammation and migration of macrophages by encouraging M1 phenotype 
differentiation and upregulation of MCP-1, osteopontin, TNFα, iNOS, IL-6 and VEGF. 
HIF-1α also promotes the formation of foam cells by reducing cholesterol efflux 
mechanisms, specifically the ABCA1 cholesterol efflux protein, and higher affinity of 
extracellular molecules for LDL. The increased level of cholesterol and triglycerides 
in the macrophages is toxic and more likely to cause cell death. This along with 
smooth muscle migration and proliferation is contributing to plaque growth and 
atherosclerosis.  
 
Figure 4. The involvement of HIF in atherosclerosis – At the early stages, HIF 
leads to the expression of reactive oxygen species (ROS) as well as iNOS, VEGF 
and NF-kB which promote increased inflammation, and then leading to endothelial 
cell dysfunction and leukocyte attachment. The accumulation of lipids and 
macrophages result in foam cell formation, and smooth muscle cell migration and 
proliferation, on which HIF exerts its effect. Finally atherosclerotic plaque forms a 
complicated lesion where hypoxia emplifies HIF expression and activation.  
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Table: Reagents displaying therapeutic potential related to HIF1α. 
 
Name of compound Inhibitor/Activator 
of HIF activity 
Mechanism of 
action 
Model of 
study 
Effect Reference 
Ad2/HIF1α/VP16 Activator Acts as HIF1α 
subunit 
dimerization 
domains and binds 
onto DNA to induce 
transcription 
No-Option 
Critical Limb 
Ischaemia 
Patients 
(Phase I) 
No- large 
improvements 
seen as 
suggested by the 
mortality and 
amputation 
percentage a 
6months and 1 
year in 
treatment group 
versus control 
(Rajagopalan 
et al., 2007) 
HIF1α/VP16 
 
Activator Acts as HIF1α 
subunit 
dimerization 
domains and binds 
onto DNA to induce 
transcription 
Rabbit Model 
hind limb 
ischaemia 
(in vivo) 
Increased EPO 
and VEGF 
expression, 
increased lactate 
dehydrogenase 
expression and 
increased 
vascularity in 
treatment group 
vs control 
(Vincent et 
al., 2000) 
Dimethyloxalylglycine 
(DMOG) 
Activator Inhibits the 
oxoglutarate-
dependent 
dioxygenase which 
normally causes 
inactivation of 
HIF1α 
Ischaemic 
Skeletal 
Muscle 
Mouse model 
(in vivo) 
Increased VEGF 
expression and 
vascularization of 
the muscles 
treated in the 
treatment group 
vs control 
(Milkiewicz 
et al., 2004) 
Adenoviral PR39 Activator Inhibits HIF1α 
breakdown by 
inhibiting the 
proteasome 
Pig Model 
Chronic 
Myocardial 
Ischaemia 
(in vivo) 
Increased 
expression of 
VEGF and its 
receptors,  
enhanced 
myocardial blood 
flow, collateral 
vessel formation 
in treatment 
group vs control 
(Post et al., 
2006) 
FG-4592 (Roxadustat) Activator Stabilize HIF via 
inhibition of PHD 
Correction of 
anemia in 
patients with 
chronic kidney 
disease 
(Phase III) 
Erythropoiesis by 
increasing 
translation of 
EPO in the 
kidneys, EPO 
receptor in 
(Besarab et 
al., 2015; 
Provenzano 
et al., 2016) 
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erythroid 
progenitors, 
divalent metal 
transporter 1 in 
duodenal 
enterocytes, 
transferrin 
receptor in 
hepatocytes 
N-acetylcysteine 
amide thiol: AD4 
Inhibitor Inhibits the 
expression of HIF1α 
Mouse 
Allergic 
Airway 
disease 
(Asthma) 
(in vivo) 
Reduced Th2 
cytokine 
production, VEGF 
expression, 
mucus 
production and 
airway resistance 
caused in allergic 
airway disease in 
treatment group 
vs control 
(Lee et al., 
2007) 
HIF-1a shRNA Inhibitor Knockdown (KD) of 
HIF1α expression 
Triple 
negative 
breast cancer 
(TNBC) cell 
lines - MDA-
MB-231 
Increased early 
and late cancer 
cell apoptosis 
(Li et al., 
2015) 
Bortezomib (PS-341) Inhibition Proteasome 
inhibitor, inhibits 
p300-HIF1α binding 
Pancreatic 
and lung 
cancers, 
multiple 
myeloma  
(Phase I) 
 
Inhibits 
angiogenesis, 
increases 
remission period 
(Befani et al., 
2012; Chen 
et al., 2011; 
Cortes et al., 
2004; 
Iskandarani 
et al., 2016; 
Kontopodis 
et al., 2016; 
Mian et al., 
2016) 
PX-478 Inhibition Inhibition of HIF1α 
deubiquitination, 
increased 
polyubiquitinated 
HIF1α levels, 
decreased HIF1α 
mRNA expression, 
inhibition of HIF1α 
translation 
Human lung 
adenocarcino
ma cell and 
small lung 
cancer cell 
(SCLC) 
injected into 
mice model 
(in vivo) 
Decreased 
mediastinal 
metastasis, 
survival time; 
decreased 
primary lung 
tumour volume 
in treatment 
groups vs 
control, results 
were more 
prominent in 
SCLC 
(Jacoby et 
al., 2010; 
Jordan et al., 
2005) 
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